Supporting the life cycle
of health technologies
A global value and access consultancy helping organisations generate evidence, demonstrate value and support patient access
How do you demonstrate value and support patient access?
From early development through to launch, organisations make decisions that shape future value, reimbursement and patient access.
Those decisions are often made amid evolving stakeholder expectations and an increasingly complex healthcare landscape.
We help organisations navigate that landscape with confidence.
Turning insight to action
Our guiding framework, Explore • Build • Optimise, helps organisations generate evidence, demonstrate value and support patient access.
Explore
In the Explore phase, we help clients identify, test and prioritise opportunities across the clinical and commercial landscape to inform business decisions.
Build
In the Build phase, we help clients define and develop evidence generation strategies to demonstrate patient-relevant value.
Optimise
In the Optimise phase, we help clients illustrate and leverage the clinical, economic and humanistic value of their products to drive patient access and uptake.
Expertise across value, access and pricing
We support organisations across global healthcare markets, from core value and access strategy through to specialised priorities and emerging market requirements.
Value & Access Advisory
Supporting value, access and pricing priorities across global healthcare markets.
European Launch & Access
Flexible support across EU launch planning, value and access strategy, and implementation.
Pricing Strategy & MFN
Understand how pricing decisions in one market may affect value, access and pricing elsewhere.
JCA Readiness & PICO Strategy
Inform evidence planning, PICO strategy and future JCA readiness.
MedTech Value & Access
Strengthen evidence, value demonstration and access for medical technologies.
JCA Readiness &
PICO Strategy
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique.
MFN-Ready Global
Pricing Strategy
We design evidence strategies that anticipate every objection before the first meeting takes place.
European Launch &
Access Partner
We translate complex data into a narrative that secures pricing, reimbursement, and patient access.
Global stakeholder community
Our community includes payers, physicians and health economic advisors, with perspectives spanning national HTA agencies and ministries of health to regional and local decision-makers. This includes a diverse payer network covering reimbursement, procurement and pathway stakeholders across public and private healthcare systems.
The map highlights the markets where we maintain active network presence and ongoing stakeholder engagement.
Oceania
Our Oceania network spans key institutions across health systems, including former senior members and advisors of health ministries, and national HTA and pricing bodies. It also includes members of state level formulary groups, clinical advisors, and senior hospital pharmacy/formulary stakeholders.
Asia
Our Asian network spans key institutions and decision-making perspectives across national and regional health systems, including former senior members and advisors of regulatory and health security authorities, HTA and pricing bodies, and national policy institutions. It also includes clinical specialists, academic health economists, and policy advisors, as well as chief and senior pharmacists and physicians across primary, secondary, tertiary, and private hospitals.
Europe
Our European network spans key institutions across health systems, including former senior members and advisors of health ministries, and national/regional HTA and pricing bodies. It also includes senior clinical, health economic, and policy advisors, hospital formulary stakeholders, and procurement specialists (including tendering).
South America
Our Latin American network spans national and regional health systems, including former members and senior advisors of health ministries, regulatory authorities, HTA and pricing bodies, and commercial insurance organisations. It also includes policy stakeholders, clinical advisors, and senior hospital pharmacy/formulary stakeholders across public and private hospitals.
North America
Our US network spans key institutions including senior members of national and regional commercial insurers, pharmacy benefit managers, integrated delivery networks, clinical pathway organisations, and hospital P&T committees. It also includes former members of CMS and the Institute for Clinical and Economic Review (ICER)
What our clients say
Feedback from clients across pharma, biotech and MedTech.
Get in touch
Speak to one of our experts about your value and access needs.
Understanding the factors that shape patient access
Explore the considerations that influence patient access.
Evidence requirements can vary between payers, HTA bodies, healthcare professionals and procurement stakeholders. Understanding which clinical, economic and real-world evidence requirements are most likely to influence decisions can help organisations prioritise evidence generation and reduce future access risks.
Demonstrating value often requires more than clinical evidence alone. Cost-effectiveness, budget impact, patient outcomes, real-world evidence and implementation considerations may all influence value perception across different stakeholders and markets.
Evidence gaps, stakeholder expectations, pricing decisions, reimbursement requirements, HTA processes and evolving policy environments can all influence value, access and pricing outcomes. Understanding these factors early can help organisations make more informed strategic decisions and reduce future risks.
Value and access pathways, reimbursement processes and evidence expectations differ across countries and healthcare systems. Understanding these differences can help organisations develop strategies that address both global and local requirements.
Understanding stakeholder expectations has always been central to effective value, access and pricing strategy. Advances in data, analytics and AI are creating new ways to identify patterns, assess evidence and explore strategic scenarios. When combined with stakeholder insight and value and access expertise, these capabilities can support more informed and confident decision-making.